Skip to main content
. 2022 Oct 24;12:984940. doi: 10.3389/fonc.2022.984940

Figure 2.

Figure 2

Survival of patients with and without liver injury after starting durvalumab based immunotherapy. The actuarial patient survival of the 21 patients who developed liver injury was significantly lower than those without liver injury (p = < 0.001 Kaplan‐Meier statistics).